Johnson & Johnson Agreed to Pay $5.5 Billion. Its Stock Went UP. Here's Why That's Not Crazy.

Here's a puzzle for you. On Monday, Johnson & Johnson announced it would pay an estimated $5.5 billion to settle roughly 76,000 lawsuits over its talc-based baby powder — and an attorney who helped negotiate the deal for plaintiffs estimated the final bill could reach $7 billion or more.

J&J's stock went up about 1%.

If markets punished companies for writing big checks, that makes no sense. But markets don't price bad news the way most people expect — and this little paradox is one of the best free lessons investing ever offers.

This article is for information and education only and is not financial advice. Nothing here is a recommendation to buy, sell, or hold any security.

The quick facts

The settlement, reported by Reuters, would resolve nearly all remaining claims that J&J's talc products caused ovarian cancer — litigation that has shadowed the company for a decade. It needs acceptance from 95% of the claimants to become final, so it isn't done yet. J&J expects to pay about $3 billion in 2027 with further payments in 2028, and the deal assigns values per claim rather than capping the total. The company continues to deny the products caused cancer and says it settled to "get closure."

(One respectful note: behind the market mechanics are tens of thousands of women with ovarian cancer claims. The settlement is, first, a resolution for them. Our subject here is narrower — what the market's reaction teaches.)

The lesson: markets hate uncertainty more than they hate costs

For ten years, anyone valuing J&J had to price an unanswerable question: what will the talc litigation ultimately cost? $2 billion? $20 billion? More? Nobody — including J&J — knew. Analysts call this an overhang: a risk of unknown size that sits on a stock and quietly discounts it year after year. Investors don't just dislike losses; they dislike unmeasurable ones, and they pay less for any company carrying one.

Monday's settlement converted an unknowable number into a known one: roughly $5.5–7 billion, paid on a schedule, by a company that generates over $20 billion in yearly profit. Painful? Yes. Survivable and plannable? Absolutely. The moment the question mark became a number, the discount attached to the question mark disappeared — and the stock rose despite the bill, because certainty itself has value.

There's a second ingredient: expectations. Markets had long assumed J&J would eventually pay something large; estimates in past years ran well above this figure. A $5.5 billion settlement, arriving after J&J had strung together courtroom wins, landed better than feared. In markets, "better than feared" and "good" trade almost identically.